Remote Oncology AI Researcher — Clinical Trials Expert

Alignerr Corp.; Seattle (WA); Remote; USD 83,000 - 152,000; Full time

Benefits offered by this job

Fully remote

Freelance autonomy

Contract extension opportunities

Job summary

Alignerr Corp. is seeking an Oncology Clinical Researcher to review and validate AI-generated oncology content. Bring real-world clinical rigor to AI development, ensuring regulatory and scientific standards are met across cancer trials.

The role is a fully remote, hourly contract for experienced oncology professionals, offering flexible scheduling and potential ongoing engagement as new projects launch.

Qualifications

• Experience designing and managing oncology clinical trials from protocol development through data readout.
• Strong background in analyzing oncology clinical data — endpoints, safety profiles, biomarkers, and treatment outcomes.
• Familiar with regulatory submission standards for agencies such as the FDA or EMA.

Responsibilities

• Evaluate AI-generated oncology insights for accuracy, regulatory alignment, and scientific validity.
• Apply trial design expertise to assess AI outputs and ensure clinical relevance.
• Review cancer trial data interpretations, including safety, efficacy, and biomarker findings.
• Identify gaps or errors in AI representations of oncology concepts, methodology, and outcomes.
• Provide structured, expert-level feedback shaping how frontier AI models reason about cancer research.
• Work independently and asynchronously on your own schedule.

Skills

Oncology trial design

Oncology data analysis

Regulatory knowledge (FDA/EMA)

Scientific writing / feedback

Independent work / remote work

Job description

Alignerr Corp. is seeking an Oncology Clinical Researcher to review and validate AI-generated oncology content. Bring real-world clinical rigor to AI development, ensuring regulatory and scientific standards are met across cancer trials.

The role is a fully remote, hourly contract for experienced oncology professionals, offering flexible scheduling and potential ongoing engagement as new projects launch.